We can generally trust that the medicines we buy at pharmacies contain what they are supposed to and that they were manufactured according to good quality standards. In his latest column, Dr Andy Gray zooms in on the regulatory scaffolding that enables this trust.
Funding cuts over the last year or so have created a crisis for multilateral health institutions. Which institutions emerge from this crisis, and in what form, will have real consequences for the health of people in South Africa, argues Spotlight editor Marcus Low.
There has been much confusion and misunderstandings about how cannabis and associated products are regulated in South Africa, with government’s own missteps adding to the uncertainty. In his last Inside The Box column for the year, Dr Andy Gray clearly sets out the current legal and regulatory situation and where we’re heading.
Evidence has been mounting that poor nutrition impacts both someone’s risk of falling ill with TB and how well they do once ill. But as the World Health Organization (WHO) releases new guidelines on TB and nutrition, it is unclear to what extent the South African government is ready to invest in providing people with nutritional support as part of the fight against TB. Biénne Huisman reports.
In several countries, the public is given an opportunity to share their views with regulators before new medicines are registered or to engage with those choosing essential medicines. In South Africa, however, opportunities for such public participation remains limited. In his latest Inside The Box column, Dr Andy Gray takes a look at how public participation is handled elsewhere and how it could be improved here.
The health department has plans to roll out lenacapavir, a twice-yearly HIV prevention injection, in a select group of public sector clinics by April 2026. Meanwhile, little progress has been made towards rolling out a two-monthly prevention injection, despite the four-year head start this product had on lenacapavir. Catherine Tomlinson reports.
